3 Specialty Chemicals Maker, Active Ingredients Leader and Over the Counter Medicines Exporter Stocks With a Strong Future Roadmap: Clean Science and Technology, Divi’s Laboratories and Marksans Pharma
- November 4, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Clean Science and Technology, Divi’s Laboratories and Marksans Pharma: ROE of 13.8% to 15.3% and FY22 to FY26 revenue CAGR of 5.1% to 18.6%. Prices as of 3 Nov 2026.
Quick Answer
The three performance chemical, API and OTC drug stocks to watch are Clean Science and Technology, Divi’s Laboratories and Marksans Pharma. Their return on equity ranges from 13.8% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 18.6%. Divi’s Laboratories has the highest return on equity at 15.3%, while Marksans Pharma has the fastest revenue growth at 18.6% a year. Prices are based on the 3 November 2026 close, and this article is educational, not investment advice.
Performance chemical, API and OTC drug stocks bring together companies with a visible plan for the years ahead. Clean Science and Technology, Divi’s Laboratories and Marksans Pharma cover a specialty chemicals maker, an active ingredients leader and an over the counter medicines maker.
This list covers three performance chemical, API and OTC drug stocks with complete current figures: Clean Science and Technology, Divi’s Laboratories and Marksans Pharma. Every figure comes from the latest reported financials and the 3 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Performance Chemical, API and OTC Drug Stocks?
Performance chemical, API and OTC drug stocks are listed companies that make performance and pharma chemicals with their own catalytic processes, produce active ingredients and custom synthesis products for global pharma firms, and make over-the-counter and prescription formulations for overseas markets. Their earnings depend on global orders and approvals.
Performance Chemical, API and OTC Drug Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Clean Science and Technology | 658.8 | 8,080 | 34.7 | 35.1 | 14.5 | 0.00 |
| Divi’s Laboratories | 10,064 | 241,311 | 82.5 | 36.0 | 15.3 | 0.00 |
| Marksans Pharma | 315.3 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
On valuation, Clean Science and Technology and Marksans Pharma trade at a P/E below the industry P/E, while Divi’s Laboratories trades above it, which reflects the growth the market already expects. Readers comparing performance chemical, API and OTC drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in performance chemical, API and OTC drug stocks can use the coming numbers to test whether growth is holding.
Why Do Performance Chemical, API and OTC Drug Stocks Have a Strong Roadmap in India?
Performance chemical, API and OTC drug stocks have a strong roadmap in India because growing demand for specialty inputs, global pharma outsourcing and rising overseas medicine use keep widening the market for these export linked companies.
- Specialty chemicals. Catalytic processes serve many end uses.
- Active ingredients. Global drug firms outsource large volumes.
- Formulations. Plants supply medicines to several markets.
Why Clean Science and Technology Features Among These Performance Chemical, API and OTC Drug Stocks
Among the performance chemical, API and OTC drug stocks on this list, Clean Science and Technology makes specialty chemicals including performance chemicals, pharma intermediates and FMCG chemicals using its own catalytic processes.
Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 230 crore, a net margin of 23.2%.
In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P/E of 34.7, below the industry P/E of 35.1.
Roadmap: The company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.
What to watch: Watch new product launches and capacity utilisation at its newer plants.
Why Divi’s Laboratories Features Among These Performance Chemical, API and OTC Drug Stocks
Among the specialty chemical and pharma shares on this list, Divi’s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.
In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%.
Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.
Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.
What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.
Why Marksans Pharma Features Among These Performance Chemical, API and OTC Drug Stocks
Among the three companies on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Clean Science and Technology vs Divi’s Laboratories vs Marksans Pharma on Key Financials
The table below sets the three performance chemical, API and OTC drug stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Clean Science and Technology | 715 | 989 | 8.5% | 230 | 23.2% |
| Divi’s Laboratories | 9,074 | 11,067 | 5.1% | 2,568 | 23.2% |
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
Divi’s Laboratories posts the highest return on equity in this group at 15.3%. Divi’s Laboratories has the largest FY26 revenue at Rs 11,067 crore, and Marksans Pharma shows the fastest revenue growth with a 18.6% compound annual rate. A useful habit with performance chemical, API and OTC drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several intermediate and formulation stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Clean Science and Technology | 256 | 291 | 13.4% |
| Divi’s Laboratories | 2,529 | 3,144 | 24.3% |
| Marksans Pharma | 626 | 866 | 38.5% |
Key Risks to Check Before Investing in Performance Chemical, API and OTC Drug Stocks
Every theme carries risks that deserve a check before any decision. For these performance chemical, API and OTC drug stocks, the main points are: Long-term specialty chemical and pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Raw material and energy costs. Input prices can move margins in chemicals.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter performance chemical, API and OTC drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Performance Chemical, API and OTC Drug Stocks
Performance chemical, API and OTC drug stocks suit investors who prefer to study business strength before price moves. Clean Science and Technology, Divi’s Laboratories and Marksans Pharma each have a clear plan to grow. Based on the 3 November 2026 close, Clean Science and Technology trades at Rs 658.8, Divi’s Laboratories at Rs 10,064 and Marksans Pharma at Rs 315.3. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these performance chemical, API and OTC drug stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track performance chemical, API and OTC drug stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are performance chemical, API and OTC drug stocks?
Ans. Performance chemical, API and OTC drug stocks are listed companies that make performance and pharma chemicals with their own catalytic processes, produce active ingredients and custom synthesis products for global pharma firms, and make over-the-counter and prescription formulations for overseas markets. Their earnings depend on global orders and approvals. This list looks at three of them, Clean Science and Technology, Divi’s Laboratories and Marksans Pharma, using reported FY22 to FY26 financials and the 3 November 2026 closing prices.
Which performance chemical, API and OTC drug stocks are covered in this list?
Ans. This list covers Clean Science and Technology, Divi’s Laboratories and Marksans Pharma. Based on the 3 November 2026 close, Clean Science and Technology traded at Rs 658.8, Divi’s Laboratories at Rs 10,064 and Marksans Pharma at Rs 315.3. Their return on equity ranges from 13.8% to 15.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 18.6%.
Why do performance chemical, API and OTC drug stocks have a strong future roadmap in India?
Ans. Performance chemical, API and OTC drug stocks have a strong roadmap in India because growing demand for specialty inputs, global pharma outsourcing and rising overseas medicine use keep widening the market for these export linked companies. The main drivers are as follows. Specialty chemicals. Catalytic processes serve many end uses. Active ingredients. Global drug firms outsource large volumes. Formulations. Plants supply medicines to several markets. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Clean Science and Technology performed financially?
Ans. Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 230 crore, a net margin of 23.2%. In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P/E of 34.7, below the industry P/E of 35.1. Looking ahead, the company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.
How has Divi’s Laboratories performed financially?
Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What risks should investors check before buying performance chemical, API and OTC drug stocks?
Ans. Investors should check a few risks before buying performance chemical, API and OTC drug stocks. Raw material and energy costs. Input prices can move margins in chemicals. Regulatory approvals. Plant inspections and approvals can affect supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of performance chemical, API and OTC drug stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 3 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.